Accuray Inc ARAY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution
-
Accuray President and Chief Executive Officer Suzanne Winter to Take Temporary Medical Leave of Absence
-
Accuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix™
-
Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results
-
Halifax Health in Florida is First in the U.S. to Treat Patients with Cancer Using the Accuray Radixact® Radiation Delivery System and VitalHold™ Technology
-
Accuray to Report Fourth Quarter Fiscal 2024 Financial Results on August 14, 2024
Trading Information
- Previous Close Price
- $1.70
- Day Range
- $1.72–1.77
- 52-Week Range
- $1.40–3.10
- Bid/Ask
- $1.51 / $1.82
- Market Cap
- $175.47 Mil
- Volume/Avg
- 466,083 / 910,488
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.39
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 987
- Website
- https://www.accuray.com
Comparables
Valuation
|
Metric
|
ARAY
|
PTGX
|
NYKD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 16.77 | — |
Price/Book Value | 3.89 | 4.88 | 0.89 |
Price/Sales | 0.39 | 8.71 | 22.66 |
Price/Cash Flow | 17.17 | 13.94 | — |
Price/Earnings
ARAY
PTGX
NYKD
Financial Strength
|
Metric
|
ARAY
|
PTGX
|
NYKD
|
|---|---|---|---|
Quick Ratio | 0.86 | 13.60 | 9.28 |
Current Ratio | 1.66 | 13.73 | 9.28 |
Interest Coverage | −0.02 | — | — |
Quick Ratio
ARAY
PTGX
NYKD
Profitability
|
Metric
|
ARAY
|
PTGX
|
NYKD
|
|---|---|---|---|
Return on Assets (Normalized) | −0.70% | 44.65% | −17.82% |
Return on Equity (Normalized) | −6.89% | 49.43% | −22.35% |
Return on Invested Capital (Normalized) | 2.32% | 44.16% | −25.52% |
Return on Assets
ARAY
PTGX
NYKD
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Dttqhbr | Kszxxs | $196.1 Bil | |||
| Stryker Corp
SYK
| Wxhqpcskw | Dky | $137.7 Bil | |||
| Boston Scientific Corp
BSX
| Ddjwkgvkx | Yrjvwny | $122.3 Bil | |||
| Medtronic PLC
MDT
| Jgnccncrk | Gcjrpy | $114.7 Bil | |||
| Edwards Lifesciences Corp
EW
| Gxvjwtgdk | Gkxncwp | $39.6 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Zxzw | Rkvv | $29.3 Bil | |||
| DexCom Inc
DXCM
| Lpjnbbppg | Qnbqk | $27.1 Bil | |||
| Steris PLC
STE
| Rnnlksjrl | Jpvpscf | $23.3 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Nskxdttkxv | Ztghw | $21.9 Bil | |||
| Insulet Corp
PODD
| Lrgjtrvnq | Bcbyzq | $16.5 Bil |
United States